Arvinas presented Phase 1 multiple-dose data showing ARV-102, an oral PROTAC targeting LRRK2, achieved roughly 50% or greater reduction of LRRK2 protein in cerebrospinal fluid by day 14 and sustained that reduction through day 28 in Parkinson’s disease patients. The trial showed dose-dependent CSF exposure consistent with blood–brain barrier penetration and biomarker reductions in endolysosomal and neuroinflammatory pathways. Results were disclosed at the AD/PD 2026 conference and reported by the company in a Globe Newswire release. Safety and tolerability were acceptable across the tested dose range, and Arvinas indicated the dataset supports further development in LRRK2-related neurodegenerative indications.